Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Selling, General & Admin history
Currency unavailable · from the income statement
No Selling, General & Admin data reported for this period type.
Selling, General & Admin vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $256.23M USD | +54.0% | +20.4% | 117.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M USD | -17.1% | +24.5% | — |
| LTM Mar 2026 | $37.63M USD | +164.2% | +95.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M USD | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $23.07M USD | +35.6% | +29.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M USD | — | +110.6% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M USD | +18.2% | +41.6% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +36.7% | +41.6% | 144.5% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.